|
Valoración de DCF de OptimizerX Corporation (OPRX)
US | Healthcare | Medical - Healthcare Information Services | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
OptimizeRx Corporation (OPRX) Bundle
¡Optimice su tiempo y mejore la precisión con nuestra calculadora DCF de OptimizerX Corporation (OPRX)! Equipado con datos auténticos y supuestos personalizables, esta herramienta le permite pronosticar, analizar y evaluar OptimizerX Corporation (OPRX) al igual que un inversor experimentado.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 24.6 | 43.3 | 61.3 | 62.5 | 71.5 | 95.5 | 127.5 | 170.2 | 227.2 | 303.3 |
| Revenue Growth, % | 0 | 76.08 | 41.51 | 1.89 | 14.53 | 33.5 | 33.5 | 33.5 | 33.5 | 33.5 |
| EBITDA | -2.8 | -.1 | 2.3 | -9.4 | -21.3 | -10.0 | -13.4 | -17.8 | -23.8 | -31.8 |
| EBITDA, % | -11.21 | -0.13721 | 3.8 | -15.08 | -29.79 | -10.48 | -10.48 | -10.48 | -10.48 | -10.48 |
| Depreciation | 1.3 | 2.1 | 2.1 | 2.0 | 2.4 | 3.8 | 5.1 | 6.8 | 9.1 | 12.1 |
| Depreciation, % | 5.21 | 4.79 | 3.4 | 3.24 | 3.36 | 4 | 4 | 4 | 4 | 4 |
| EBIT | -4.0 | -2.1 | .2 | -11.4 | -23.7 | -13.8 | -18.5 | -24.7 | -32.9 | -43.9 |
| EBIT, % | -16.43 | -4.93 | 0.39152 | -18.32 | -33.15 | -14.49 | -14.49 | -14.49 | -14.49 | -14.49 |
| Total Cash | 18.9 | 10.5 | 84.7 | 74.1 | 13.9 | 61.2 | 81.7 | 109.0 | 145.5 | 194.3 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 7.4 | 17.9 | 24.8 | 22.2 | 37.3 | 38.1 | 50.9 | 67.9 | 90.7 | 121.0 |
| Account Receivables, % | 30.16 | 41.29 | 40.46 | 35.48 | 52.14 | 39.91 | 39.91 | 39.91 | 39.91 | 39.91 |
| Inventories | .0 | .0 | -5,630,649.4 | 1.8 | .0 | -18.5 | -24.8 | -33.1 | -44.1 | -58.9 |
| Inventories, % | 0 | 0 | -9186507.92 | 2.89 | 0 | -19.42 | -19.42 | -19.42 | -19.42 | -19.42 |
| Accounts Payable | .5 | .6 | .6 | 1.5 | 2.2 | 1.9 | 2.6 | 3.4 | 4.6 | 6.1 |
| Accounts Payable, % | 2 | 1.43 | 0.99002 | 2.48 | 3.11 | 2 | 2 | 2 | 2 | 2 |
| Capital Expenditure | -1.6 | -.1 | -.5 | -.2 | -.9 | -1.7 | -2.3 | -3.1 | -4.2 | -5.5 |
| Capital Expenditure, % | -6.45 | -0.28796 | -0.79292 | -0.39162 | -1.22 | -1.83 | -1.83 | -1.83 | -1.83 | -1.83 |
| Tax Rate, % | 30.19 | 30.19 | 30.19 | 30.19 | 30.19 | 30.19 | 30.19 | 30.19 | 30.19 | 30.19 |
| EBITAT | -3.1 | -2.3 | .2 | -10.6 | -16.6 | -11.4 | -15.2 | -20.3 | -27.2 | -36.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -10.4 | -10.7 | 5,630,644.2 | -5,630,656.4 | -27.7 | 8.1 | -18.4 | -24.5 | -32.8 | -43.7 |
| WACC, % | 8.53 | 8.82 | 8.46 | 8.72 | 8.42 | 8.59 | 8.59 | 8.59 | 8.59 | 8.59 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -79.8 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -45 | |||||||||
| Terminal Value | -677 | |||||||||
| Present Terminal Value | -448 | |||||||||
| Enterprise Value | -528 | |||||||||
| Net Debt | 23 | |||||||||
| Equity Value | -551 | |||||||||
| Diluted Shares Outstanding, MM | 17 | |||||||||
| Equity Value Per Share | -32.19 |
What You Will Receive
- Adjustable Forecast Inputs: Effortlessly modify assumptions (growth %, margins, WACC) to explore various scenarios.
- Comprehensive Data: OptimizeRx Corporation’s financial information pre-loaded to facilitate your analysis.
- Instant DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
- Tailored and Professional: A refined Excel model that customizes to fit your valuation requirements.
- Designed for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and streamlining your workflow.
Key Features
- Comprehensive DCF Calculator: Features in-depth unlevered and levered DCF valuation models tailored for OptimizeRx Corporation (OPRX).
- WACC Calculator: Comes with a pre-configured Weighted Average Cost of Capital sheet that allows for customizable inputs.
- Adjustable Forecast Assumptions: Easily alter growth rates, capital expenditures, and discount rates to fit your analysis.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios specifically for OptimizeRx Corporation (OPRX).
- User-Friendly Dashboard and Charts: Visual representations of key valuation metrics facilitate straightforward analysis.
How It Works
- 1. Access the Template: Download and open the Excel file containing OptimizeRx Corporation's (OPRX) financial data.
- 2. Adjust Key Inputs: Modify essential parameters such as revenue growth, discount rates, and investment expenditures.
- 3. See Immediate Results: The DCF model automatically computes the intrinsic value and net present value (NPV).
- 4. Explore Different Scenarios: Analyze various forecasts to evaluate multiple valuation possibilities.
- 5. Present with Assurance: Deliver expert valuation analyses to bolster your strategic decisions.
Why Choose This Calculator for OptimizeRx Corporation (OPRX)?
- Designed for Experts: A sophisticated tool utilized by financial analysts, CFOs, and industry consultants.
- Accurate Financial Data: OptimizeRx’s historical and forecasted financials are preloaded for precision.
- Forecast Simulation: Effortlessly test various scenarios and assumptions.
- Comprehensive Results: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Step-by-step guidance simplifies the entire process.
Who Should Use This Product?
- Investors: Accurately assess OptimizeRx Corporation’s (OPRX) fair value prior to making investment decisions.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis related to OptimizeRx Corporation (OPRX).
- Consultants: Efficiently customize the template for valuation reports for clients involving OptimizeRx Corporation (OPRX).
- Entrepreneurs: Acquire insights into financial modeling practices employed by leading healthcare companies, including OptimizeRx Corporation (OPRX).
- Educators: Implement it as a teaching resource to illustrate valuation methodologies with a focus on OptimizeRx Corporation (OPRX).
What the Template Contains
- Preloaded OPRX Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.